US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
2seventy bio Inc (TSVT)
2seventy bio Inc (TSVT) ニュース

2seventy bio Inc (TSVT)

5.00

0.00

( 0.00% )

更新日時： 09:00:00

個人投資家向けのプロ仕様のツール。

プレミアム

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form EFFECT - Notice of Effectiveness

Form POS AM - Post-Effective amendments for registration statement

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form 8-K - Current report

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer...

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

molee

$TSVT $5.00 per share, all-cash transaction .

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

Invest-in-America

Invest-in-America 2年前

TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"

Monksdream

Monksdream 2年前

TSVT 10Q due March 5

molee

$TSVT > A bit of "short covering" going on now ... How high ???

Monksdream

Monksdream 3年前

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

johnhancoque

johnhancoque 3年前

2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.

molee

C'mon man . What the heck . $2.00 now ? Really ?

Simpson Manufacturing

Amundi Label ISR Credit ...

Triton Bond Trust 2021 1...

4625% until 11/03/2028 4...

Cocrystal Pharma

American Electric Power

Franklin LibertyShares I... (GM)

State Street SPDR S&P Em...

Corevalues America First...

China Southern Airlines

BlackRock Investment Man...

Lark Distilling (PK)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。